Yan Leyfman: Off-the-shelf CAR T cells could be a viable option for R/R T-cell Lymphoma
Yan Leyfman, Co-founder and executive director of MedNews Week, shared an article Swaminathan P. Iyer and colleagues authored on LinkedIn:
“New study spearheaded by researchers from MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center on CTX130, a CAR T-cell therapy for relapsed/refractory T-cell lymphoma, has been completed across the USA, Australia, and Canada. The phase 1 trial included 39 heavily pre-treated patients.
Key Findings:
Safety: Manageable, with cytokine release syndrome being the most common side effect (67% of patients).
Efficacy: 46.2% of patients showed an objective response, with improved results at higher doses (51.6%).
This study indicates that off-the-shelf CAR T cells could be a viable option. Next, CTX131, an enhanced version, is in development.”
Authors: Swaminathan P. Iyer et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023